Proteomics

Dataset Information

0

Proteomic characterization of ESR1 mutant cells


ABSTRACT: Three quarters of all breast cancer cases express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancers, in particular to aromatase inhibitors. ESR1 mutations promote constitutive ER activity and affect other signaling pathways, allowing cancer cells to proliferate by employing mechanisms within and outwith direct regulation by the ER. Although subjected to extensive genetic and transcriptomic analyses, understanding of protein alterations remains poorly investigated. Towards this, we employed an integrated mass spectrometry (MS) based proteomic approach to profile the protein and phosphoprotein differences in breast cancer cell lines expressing the frequent Y537N and Y537S ER mutations. Global proteome analysis revealed enrichment of mitotic and immune signaling pathways in ER mutant cells, while phosphoprotein analysis evidenced enriched activity of proliferation associated kinases, in particular CDKs and MTOR. Integration of protein expression and phosphorylation data revealed pathway-dependent discrepancies (motility vs proliferation) that were observed at varying degrees across mutant and wt ER cells. Additionally, protein expression and phosphorylation patterns, while under different regulation, still recapitulated the estrogen-independent phenotype of ER mutant cells.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Breast Cancer

SUBMITTER: Tommaso De Marchi  

LAB HEAD: Emma Nimeus

PROVIDER: PXD032369 | Pride | 2024-03-26

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
HS_sp_CANnISO_20200224.fasta Fasta
TDM_J1905_003.raw Raw
TDM_J1905_004.raw Raw
TDM_J1905_005.raw Raw
TDM_J1905_007.raw Raw
Items per page:
1 - 5 of 184
altmetric image

Publications


Three quarters of all breast cancers express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancer, in particular to aromatase inhibitors. ESR1 mutations promote constitutive ER activity and affect other signaling pathways, allowing cancer cells to proliferate by employing mechanisms within and without direct regulation by the ER. Although su  ...[more]

Similar Datasets

2024-03-26 | PXD032285 | Pride
2024-03-26 | PXD046446 | Pride
2021-09-09 | PXD020666 | Pride
2012-11-26 | E-GEOD-40129 | biostudies-arrayexpress
2022-10-13 | PXD029525 | Pride
2016-10-25 | E-GEOD-78285 | biostudies-arrayexpress
2010-05-26 | E-GEOD-10800 | biostudies-arrayexpress
2016-08-09 | E-GEOD-76454 | biostudies-arrayexpress
2014-05-06 | E-GEOD-23850 | biostudies-arrayexpress
2010-12-31 | E-GEOD-23445 | biostudies-arrayexpress